menu
    • menu

    Company profile for Hisamitsu Pharmaceutical Co., Inc.

    NEW Drugs in Dev: 1
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    1847 Komatsuya founded (Nihei Hisamitsu) 1869 KISHINTAN launched 1871 The company name, Komatsuya, changed to Hisamitsu Joeido (Yoichi Hisamitsu) 1903 Hisamitsu & Co. (Saburo Nakatomi) established ASAHI MANKINKO® launched 1907 KAIFUKUGAN® launched 1934 SALONPAS® launched 1944 Hisamitsu＆Co. played a leading role in the incorporation of Miyaki Seiyaku Co. 1951 Hisamitsu＆Co. incorporated (Masayoshi Nakatomi) 1952 Osaka Re...
    1847 Komatsuya founded (Nihei Hisamitsu) 1869 KISHINTAN launched 1871 The company name, Komatsuya, changed to Hisamitsu Joeido (Yoichi Hisamitsu) 1903 Hisamitsu & Co. (Saburo Nakatomi) established ASAHI MANKINKO® launched 1907 KAIFUKUGAN® launched 1934 SALONPAS® launched 1944 Hisamitsu＆Co. played a leading role in the incorporation of Miyaki Seiyaku Co. 1951 Hisamitsu＆Co. incorporated (Masayoshi Nakatomi) 1952 Osaka Representative Office (current Osaka Branch) established 1957 Tokyo Representative Office (current Tokyo Head Office and Branch) established 1960 Taiwan Hisamitsu Pharmaceutical Co., Ltd. (current Taipei Branch) established 1962 The company’s stocks listed in the Second Section of the Tokyo Stock Exchange; Shares listed on the Fukuoka Stock Exchange 1963 AIR® SALONPAS launched 1964 Shares listed in the Second Section of the Osaka Stock Exchange 1965 The company renamed Hisamitsu Pharmaceutical Co., Inc. 1966 Nagoya Representative Office (currently Nagoya Branch) established 1968 SALONPAS® E launched 1970 Sapporo Representative Office (current Sapporo Branch) established 1971 SALONSIP® launched Shares listed in the Second Section of the Nagoya Stock Exchange Construction of the Tosu Laboratories completed Sendai Representative Office (current Sendai Branch) established 1972 Section to the First Section of the Tokyo Shares shifted from the Second Stock Exchange, Osaka Stock Exchange and Nagoya Stock Exchange PAPSALON® launched 1975 P.T. Salonpas Indonesia established 1978 PAPSALON® G launched 1981 Masayoshi Nakatomi became a Chairman of the Board of Directors and Hirotaka Nakatomi took a charge of president & CEO 1982 SALONPAS-HI® launched 1983 Takamatsu Representative Office (current Takamatsu Branch) established Hiroshima Representative Office (current Hiroshima Branch) established 1984 VESICUM® (cream and ointment) launched 1985 SALONPAS® A launched 1986 Hisamitsu Farmaceutica do Brazil Ltda. established SALONPAS® 30 launched ANAAKI SALONPAS® A (Porous SALONPAS® A) launched SECTOR® GEL launched 1987 Hisamitsu America, Inc. established NOBINOBI® SALONSIP® launched Construction of Utsunomiya Factory completed 1988 The Nakatomi Foundation for Promotion of Health Science established MOHRUS® launched 1989 Hisamitsu’s corporate new logo used SECTOR® (cream and lotion) launched 1990 Construction of Tsukuba Laboratories completed Nakatomi Memorial Foundation established 1991 AIR® SALONPAS® EX launched 1992 VOLLEY® (cream and lotion) launched 1993 SALONSIP® HEAD PAD launched 1994 Hisamitsu’s corporate logo changed Hisamitsu KBC Augusta Golf Tournament held Hisamitsu Vietnam Pharmaceutical Co., Ltd. established 1995 Nakatomi Memorial Medicine Museum opened Operations at the Factory in Vietnam started MOHRUS® TAPE launched 1997 SALONPAS® Ae launched 1998 California Laboratories established London Representative Office (current Hisamitsu UK Ltd.) established Kumamoto Sales Office (current Kumamoto Branch) established La SALONPAS® launched Lifecella® Face Mask® launched NOBINOBI® SALONSIP® -α launched 1999 Acquires ISO 14001 Certification (Kyushu Head Office) 2000 Kyoto Sales Office (currently Kyoto Branch) established ESTRANA® launched Acquired ISO 14001 Certification (Utsunomiya Factory) 2001 Tokyo Head Office relocated to Marunouchi,Tokyo 2002 Operations at Manaus Factory in Brazil started MOHRUS® TAPE L launched Malaysia Representative Office (current Singapore Branch) established Lifecella® Essence Sheet Mask launched Hisamitsu UK Ltd. established 2003 Hisamitsu’s corporate logo changed BUTENALOCK® launched FEITAS® launched FLEX® launched Taipei Branch established 2004 The honorary consulate of Brazil opened. AIR® SALONPAS® Indomethacin 1.0% launched 2005 New Jersey Representative Office established Hisamitsu took over the ethical drugs division from SSP co.,Ltd (Hisamitsu Medical Co., Ltd. founded) MOHRUS® 60 launched KEPLAT® launched in Italy MOHRUS® PATCH launched in Hong Kong SALONPAS World Ladies Golf Tournament (currently LPGA Tour World Ladies Championship SALONPAS CUP) held SALONSIP® L launched 2006 Kagoshima Branch established Roma Representative Office (integrated with Hisamitsu UK Ltd.) established Lifecella® Gel Mask launched NOBINOBI® SALONSIP® S launched FEITAS® (lotion, cream and tick) launched TULOBUTEROL TAPE “HMT” launched NABOAL® PAP launched NABOAL® TAPE L launched 2007 Hisamitsu celebrated the 160th anniversary of the company’s founding Lifecella® Milky Lotion Sheet Mask launched FEITAS® L launched Singapore Branch established SALONPAS® LOTION launched Construction of the Utsunomiya Second Factory completed FEITAS® HOT launched CSR Promotion Office established The NAS Battery System inplemented 2008 SALONPAS® PAIN RELIEF PATCH was approved by the US-FDA BUTENALOCK® V launched AIR® SALONPAS® DX launched GAN RYO JUN® launched SALONPAS® EX launched FEITAS® L HOT launched FEITAS® (gel, tick and gel-patch) launched Lifecella® Essence Mask (3 items) launched 2009 Lifecella® Eye Mask (3 items) launched Hisamitsu® ICING SHEET launched AIR® SALONPAS® ICING SPRAY launched CHOLESTON® launched FEITAS® Z (tape, gel-patch and gel) launched Hisamitsu U.S., Inc.established Noven Pharmaceuticals, Inc. (U.S.A.) integrated FEITAS® SIP HOT launched SALONPAS® EX HOT launched 2010 BUTENALOCK® V AIR® SOKAI POWDER launched Hisamitsu® ICE TOWEL launched Fentany Transdermal System launched in the U.S FENTOS® TAPE launched

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hisamitsu Pharmaceutical Co., Inc.japan Flag
    Country
    Country
    Japan
    Address
    Address
    Kyushu Head Office (Registered head office) Saga, Tosu, Tashirodaikan-machi 40...
    Telephone
    Telephone
    +81-(0)3-5293-1720
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hisamitsu.co.jp/english/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO
    Japan's Hisamitsu Pharmaceutical plans $2.55 billion MBO

    07 Jan 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/japans-hisamitsu-pharmaceutical-plans-255-billion-mbo-2026-01-07/

    REUTERS
    07 Jan 2026
    Share Share
    Noven Debuts ADHD Mindful Patch Companion App at APSARD 2025
    Noven Debuts ADHD Mindful Patch Companion App at APSARD 2025

    14 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250114916087/en

    BUSINESSWIRE
    14 Jan 2025
    Share Share
    Hisamitsu launches Salonpas Diclofenac Patch 1% for pain relief
    Hisamitsu launches Salonpas Diclofenac Patch 1% for pain relief

    03 Nov 2023

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/23263/hisamitsu-pharma-launches-salonpas-diclofenac-patch-1-in-singapore-for-pain-relief.html

    BIOSPECTRUM ASIA
    03 Nov 2023
    Share Share
    Hisamitsu Ordered to Suspend Biz over Salonpas OTC Data Tampering
    Hisamitsu Ordered to Suspend Biz over Salonpas OTC Data Tampering

    13 Aug 2021

    // JIHO

    https://pj.jiho.jp/article/244999

    JIHO
    13 Aug 2021
    Share Share
    SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch
    SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch

    13 Apr 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200413005414/en

    BUSINESSWIRE
    13 Apr 2020
    Share Share
    FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia
    FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia

    15 Oct 2019

    // BIOSPACE

    https://www.biospace.com/article/fda-approves-noven-pharmaceuticals-transdermal-patch-for-schizophrenia/?s=95

    BIOSPACE
    15 Oct 2019
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail

    Details:

    HTU-520 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.


    Lead Product(s): Terbinafine Hydrochloride

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 22, 2011

    blank

    01

    Hisamitsu Pharmaceutical Co., Inc.

    Japan
    arrow
    BePharma
    Not Confirmed

    Hisamitsu Pharmaceutical Co., Inc.

    Japan
    arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Terbinafine Hydrochloride

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toena...

    Details : HTU-520 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onychomycosis.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 22, 2011

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    ABOUT THIS PAGE

    Contact Hisamitsu Pharmaceutical Co Inc and get a quotation

    Hisamitsu Pharmaceutical Co Inc is a supplier offers 4 products (APIs, Excipients or Intermediates).

    Find a price of Asenapine Maleate bulk with DMF offered by Hisamitsu Pharmaceutical Co Inc

    Find a price of Diclofenac Sodium bulk with DMF offered by Hisamitsu Pharmaceutical Co Inc

    Find a price of HP-3150 TRANSDERMAL SYSTEM bulk with DMF offered by Hisamitsu Pharmaceutical Co Inc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TOKYO, JAPAN. bulk offered by Hisamitsu Pharmaceutical Co Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search